The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2012Intestinal and Nasal Microbiota of Patients with Idiopathic Parkinson's disease
Objective/Rationale:
The cause of Parkinson’s disease is unknown and a reliable biomarker to identify Parkinson’s disease patients as early as possible is urgently needed. Nerve cells near the nose... -
Dyskinesia Challenge, 2012The Role of CK2 in the Development of Levodopa-Induced Dyskinesia in Parkinson’s disease
Promising Outcomes of Original Grant:
In Parkinson’s disease, dopamine-producing neurons degenerate, leading to a lack of dopamine in the brain. This leads to profound changes in the cells which are... -
Rapid Response Innovation Awards, 2012Reversing Pre-existing Pathologies of Dopamine Neurons in an Alpha-synuclein Model
Objective/Rationale:
Alpha-synuclein has been identified to play the central role in Parkinson’s disease. Genome-wide association studies confirm alpha-synuclein as a risk factor for... -
Therapeutics Development Initiative, 2012Anti-parkinsonian and Anti-dyskinetic Efficacy of HE3286 in a Model of Parkinson’s Disease
Objective/Rationale:
HE3286 is an anti-inflammatory drug in phase II clinical trials for other diseases that is being evaluated for treatment of Parkinson’s disease (PD). HE3286 taken orally rapidly... -
Biomarker Development, 2012The Fox Investigation for New Discovery of Biomarkers (BioFIND)
Objective/Rationale:
Biomarkers — a biological marker of disease presence or risk like cholesterol level for heart disease — will greatly aid clinicians’ ability to diagnose Parkinson’s... -
Target Validation, 2012VPS35 as a Novel Target for Parkinson's Disease
Objective/Rationale:
Mutations in the VPS35 gene were recently identified as a cause of autosomal dominant familial Parkinson's disease (PD). How mutations in VPS35 precipitate the demise of...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.